Twofold overexpression of human β-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury

Hisayuki Murai, Jean E S Pierce, Ramesh Raghupathi, Douglas H. Smith, Kathryn E. Saatman, John Q. Trojanowski, Virginia M Y Lee, Jeanne F. Loring, Chris Eckman, Steven G Younkin, Tracy K. Mcintosh

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

By using transgenic mice that overexpress human β-amyloid precursor proteins (APPs) at levels twofold higher than endogenous APPs, following introduction of the human APP gene in a yeast artificial chromosome (YAC), we examined the effects of controlled cortical impact (CCI) brain injury on neuromotor/cognitive dysfunction and the development of Alzheimer's disease (AD)-like neuropathology. Neuropathological analyses included Nissl-staining and immunohistochemistry to detect APPs, β-amyloid (Aβ), neurofilament proteins, and glial fibrillary acidic protein, whereas Aβ levels were measured in brain homogenates from mice subjected to CCI and control mice by using a sensitive sandwich enzyme-linked immunosorbent assay. Twenty APP-YAC transgenic mice and 17 wild type (WT) littermate controls were anesthetized and subjected to CCI (velocity, 5 m/second; deformation depth, I ram). Sham (anesthetized but uninjured) controls (n = 10 APP-YAC; n = 8 WT) also were studied. Motor function was evaluated by using rotarod, inclined-plane, and forelimb/hindlimb flexion tests. The Morris water maze was used to assess memory. Although CCI induced significant motor dysfunction and cognitive deficits, no differences were observed between brain-injured APP-YAC mice and WT mice at 24 hours and 1 week postinjury. By 1 week postinjury, both cortical and hippocampal CA3 neuron loss as well as extensive astrogliosis were observed in all injured animals, suggesting that overexpression of human APPs exhibited no neuroprotective effects. Although AD-like pathology (including amyloid plaques) was not observed in either sham or brain-injured animals, a significant decrease in brain concentrations of only Aβ terminating at amino acid 40 (Aβx-40) was observed following brain injury in APP-YAC mice (P ≤ 0.05 compared with sham control levels). Our data show that the APP-YAC mice do not develop AD-like neuropathology following traumatic brain injury. This may be because this injury does not induce elevated levels of the more amyloidogenic forms of human Aβ (i.e., Aβx- 42/43) in these mice.

Original languageEnglish (US)
Pages (from-to)428-438
Number of pages11
JournalJournal of Comparative Neurology
Volume392
Issue number4
DOIs
StatePublished - Mar 23 1998

Fingerprint

Amyloid beta-Protein Precursor
Brain Injuries
Transgenic Mice
Yeast Artificial Chromosomes
Alzheimer Disease
Brain
Neurofilament Proteins
Serum Amyloid A Protein
Chromosomes, Human, Pair 8
Forelimb
Glial Fibrillary Acidic Protein
Amyloid Plaques
Neuroprotective Agents
Hindlimb
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Pathology
Staining and Labeling
Neurons
Amino Acids

Keywords

  • β-amyloid peptides
  • Alzheimer's disease
  • Amyloid plaques
  • Traumatic brain injury

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Twofold overexpression of human β-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury. / Murai, Hisayuki; Pierce, Jean E S; Raghupathi, Ramesh; Smith, Douglas H.; Saatman, Kathryn E.; Trojanowski, John Q.; Lee, Virginia M Y; Loring, Jeanne F.; Eckman, Chris; Younkin, Steven G; Mcintosh, Tracy K.

In: Journal of Comparative Neurology, Vol. 392, No. 4, 23.03.1998, p. 428-438.

Research output: Contribution to journalArticle

Murai, Hisayuki ; Pierce, Jean E S ; Raghupathi, Ramesh ; Smith, Douglas H. ; Saatman, Kathryn E. ; Trojanowski, John Q. ; Lee, Virginia M Y ; Loring, Jeanne F. ; Eckman, Chris ; Younkin, Steven G ; Mcintosh, Tracy K. / Twofold overexpression of human β-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury. In: Journal of Comparative Neurology. 1998 ; Vol. 392, No. 4. pp. 428-438.
@article{c56e453fea3c43278df48b2b7013bdea,
title = "Twofold overexpression of human β-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury",
abstract = "By using transgenic mice that overexpress human β-amyloid precursor proteins (APPs) at levels twofold higher than endogenous APPs, following introduction of the human APP gene in a yeast artificial chromosome (YAC), we examined the effects of controlled cortical impact (CCI) brain injury on neuromotor/cognitive dysfunction and the development of Alzheimer's disease (AD)-like neuropathology. Neuropathological analyses included Nissl-staining and immunohistochemistry to detect APPs, β-amyloid (Aβ), neurofilament proteins, and glial fibrillary acidic protein, whereas Aβ levels were measured in brain homogenates from mice subjected to CCI and control mice by using a sensitive sandwich enzyme-linked immunosorbent assay. Twenty APP-YAC transgenic mice and 17 wild type (WT) littermate controls were anesthetized and subjected to CCI (velocity, 5 m/second; deformation depth, I ram). Sham (anesthetized but uninjured) controls (n = 10 APP-YAC; n = 8 WT) also were studied. Motor function was evaluated by using rotarod, inclined-plane, and forelimb/hindlimb flexion tests. The Morris water maze was used to assess memory. Although CCI induced significant motor dysfunction and cognitive deficits, no differences were observed between brain-injured APP-YAC mice and WT mice at 24 hours and 1 week postinjury. By 1 week postinjury, both cortical and hippocampal CA3 neuron loss as well as extensive astrogliosis were observed in all injured animals, suggesting that overexpression of human APPs exhibited no neuroprotective effects. Although AD-like pathology (including amyloid plaques) was not observed in either sham or brain-injured animals, a significant decrease in brain concentrations of only Aβ terminating at amino acid 40 (Aβx-40) was observed following brain injury in APP-YAC mice (P ≤ 0.05 compared with sham control levels). Our data show that the APP-YAC mice do not develop AD-like neuropathology following traumatic brain injury. This may be because this injury does not induce elevated levels of the more amyloidogenic forms of human Aβ (i.e., Aβx- 42/43) in these mice.",
keywords = "β-amyloid peptides, Alzheimer's disease, Amyloid plaques, Traumatic brain injury",
author = "Hisayuki Murai and Pierce, {Jean E S} and Ramesh Raghupathi and Smith, {Douglas H.} and Saatman, {Kathryn E.} and Trojanowski, {John Q.} and Lee, {Virginia M Y} and Loring, {Jeanne F.} and Chris Eckman and Younkin, {Steven G} and Mcintosh, {Tracy K.}",
year = "1998",
month = "3",
day = "23",
doi = "10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2",
language = "English (US)",
volume = "392",
pages = "428--438",
journal = "Journal of Comparative Neurology",
issn = "0021-9967",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Twofold overexpression of human β-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury

AU - Murai, Hisayuki

AU - Pierce, Jean E S

AU - Raghupathi, Ramesh

AU - Smith, Douglas H.

AU - Saatman, Kathryn E.

AU - Trojanowski, John Q.

AU - Lee, Virginia M Y

AU - Loring, Jeanne F.

AU - Eckman, Chris

AU - Younkin, Steven G

AU - Mcintosh, Tracy K.

PY - 1998/3/23

Y1 - 1998/3/23

N2 - By using transgenic mice that overexpress human β-amyloid precursor proteins (APPs) at levels twofold higher than endogenous APPs, following introduction of the human APP gene in a yeast artificial chromosome (YAC), we examined the effects of controlled cortical impact (CCI) brain injury on neuromotor/cognitive dysfunction and the development of Alzheimer's disease (AD)-like neuropathology. Neuropathological analyses included Nissl-staining and immunohistochemistry to detect APPs, β-amyloid (Aβ), neurofilament proteins, and glial fibrillary acidic protein, whereas Aβ levels were measured in brain homogenates from mice subjected to CCI and control mice by using a sensitive sandwich enzyme-linked immunosorbent assay. Twenty APP-YAC transgenic mice and 17 wild type (WT) littermate controls were anesthetized and subjected to CCI (velocity, 5 m/second; deformation depth, I ram). Sham (anesthetized but uninjured) controls (n = 10 APP-YAC; n = 8 WT) also were studied. Motor function was evaluated by using rotarod, inclined-plane, and forelimb/hindlimb flexion tests. The Morris water maze was used to assess memory. Although CCI induced significant motor dysfunction and cognitive deficits, no differences were observed between brain-injured APP-YAC mice and WT mice at 24 hours and 1 week postinjury. By 1 week postinjury, both cortical and hippocampal CA3 neuron loss as well as extensive astrogliosis were observed in all injured animals, suggesting that overexpression of human APPs exhibited no neuroprotective effects. Although AD-like pathology (including amyloid plaques) was not observed in either sham or brain-injured animals, a significant decrease in brain concentrations of only Aβ terminating at amino acid 40 (Aβx-40) was observed following brain injury in APP-YAC mice (P ≤ 0.05 compared with sham control levels). Our data show that the APP-YAC mice do not develop AD-like neuropathology following traumatic brain injury. This may be because this injury does not induce elevated levels of the more amyloidogenic forms of human Aβ (i.e., Aβx- 42/43) in these mice.

AB - By using transgenic mice that overexpress human β-amyloid precursor proteins (APPs) at levels twofold higher than endogenous APPs, following introduction of the human APP gene in a yeast artificial chromosome (YAC), we examined the effects of controlled cortical impact (CCI) brain injury on neuromotor/cognitive dysfunction and the development of Alzheimer's disease (AD)-like neuropathology. Neuropathological analyses included Nissl-staining and immunohistochemistry to detect APPs, β-amyloid (Aβ), neurofilament proteins, and glial fibrillary acidic protein, whereas Aβ levels were measured in brain homogenates from mice subjected to CCI and control mice by using a sensitive sandwich enzyme-linked immunosorbent assay. Twenty APP-YAC transgenic mice and 17 wild type (WT) littermate controls were anesthetized and subjected to CCI (velocity, 5 m/second; deformation depth, I ram). Sham (anesthetized but uninjured) controls (n = 10 APP-YAC; n = 8 WT) also were studied. Motor function was evaluated by using rotarod, inclined-plane, and forelimb/hindlimb flexion tests. The Morris water maze was used to assess memory. Although CCI induced significant motor dysfunction and cognitive deficits, no differences were observed between brain-injured APP-YAC mice and WT mice at 24 hours and 1 week postinjury. By 1 week postinjury, both cortical and hippocampal CA3 neuron loss as well as extensive astrogliosis were observed in all injured animals, suggesting that overexpression of human APPs exhibited no neuroprotective effects. Although AD-like pathology (including amyloid plaques) was not observed in either sham or brain-injured animals, a significant decrease in brain concentrations of only Aβ terminating at amino acid 40 (Aβx-40) was observed following brain injury in APP-YAC mice (P ≤ 0.05 compared with sham control levels). Our data show that the APP-YAC mice do not develop AD-like neuropathology following traumatic brain injury. This may be because this injury does not induce elevated levels of the more amyloidogenic forms of human Aβ (i.e., Aβx- 42/43) in these mice.

KW - β-amyloid peptides

KW - Alzheimer's disease

KW - Amyloid plaques

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=0032536811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032536811&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2

DO - 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2

M3 - Article

VL - 392

SP - 428

EP - 438

JO - Journal of Comparative Neurology

JF - Journal of Comparative Neurology

SN - 0021-9967

IS - 4

ER -